To access publisher's full text version of this article click on the hyperlink belowThe NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1-45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5% on day 29 or ≥0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69-0.81), being 0.82 (0.74-0.88) for patients 1.0-9.9 years, 0.76 (0.66-0.86) for those 10.0-17....
To access publisher's full text version of this article click on the hyperlink at the bottom of the ...
Background: Treating adolescents and young adults (AYA) patients with acute lymphoblastic leukemia (...
Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is 480%. Outcom...
To access publisher's full text version of this article click on the hyperlink belowAdults with acut...
Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordi...
To access publisher's full text version of this article click on the hyperlink belowThe population-b...
Purpose Retrospective comparisons have suggested that adolescents or teenagers with acute lymphoblas...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
International audiencePURPOSE:This study evaluated the efficacy of pediatric-like acute lymphoblasti...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
Purpose: The International Berlin-Frankfurt-Münster (BFM) study group conducted a study on pediatri...
To access publisher's full text version of this article click on the hyperlink belowThromboembolism ...
To access publisher's full text version of this article click on the hyperlink belowBACKGROUND: Trea...
PURPOSE: This study evaluated the efficacy of pediatric-like acute lymphoblastic leukemia (ALL) ther...
To access publisher's full text version of this article click on the hyperlink at the bottom of the ...
Background: Treating adolescents and young adults (AYA) patients with acute lymphoblastic leukemia (...
Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is 480%. Outcom...
To access publisher's full text version of this article click on the hyperlink belowAdults with acut...
Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordi...
To access publisher's full text version of this article click on the hyperlink belowThe population-b...
Purpose Retrospective comparisons have suggested that adolescents or teenagers with acute lymphoblas...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
International audiencePURPOSE:This study evaluated the efficacy of pediatric-like acute lymphoblasti...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
Purpose: The International Berlin-Frankfurt-Münster (BFM) study group conducted a study on pediatri...
To access publisher's full text version of this article click on the hyperlink belowThromboembolism ...
To access publisher's full text version of this article click on the hyperlink belowBACKGROUND: Trea...
PURPOSE: This study evaluated the efficacy of pediatric-like acute lymphoblastic leukemia (ALL) ther...
To access publisher's full text version of this article click on the hyperlink at the bottom of the ...
Background: Treating adolescents and young adults (AYA) patients with acute lymphoblastic leukemia (...
Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is 480%. Outcom...